Skin penetration enhancing components
AssigneeWyeth
InventorsAnthony David Ormerod, Arthur Winfield
Life of this patent
Estimating the term…
Abstract
The present invention relates to a topical formulation for the treatment of a dermatological condition which comprises a macrocyclic lactone antibiotic, immunosuppresive macrolide or a biologically active analogue, derivative or pro-drug thereof; characterized in that it further comprises a permeation modulator and the permeation modulator and the macrocyclic lactone or macrolide or the biologically active analogue, derivative or pro-drug thereof are present in relative amounts such that when a therapeutic amount is applied to the skin a minimal systemic effect is produced. The immunosuppressive macrolide may be sirolimus.
Claims28
A topical formulation for the treatment of a dermatological condition which comprises a macrocyclic lactone antibiotic chosen from clarithromycin or an immunosuppressive macrolide chosen from sirolimus or SDZ ASM 981, and a permeation modulator which are present in relative amounts such that when a therapeutic amount is applied to the skin a minimal systemic effect is produced.
A topical formulation for the treatment of a dermatological condition which comprises a macrocyclic tactone antibiotic chosen from azithromycin or clarithromycin or an immunosuppressive macrolide chosen from sirolimus, FK506 or SDZ ASM 981, and a permeation modulator which are present in relative amounts such that when a therapeutic amount is applied to the skin a minimal systemic effect is produced and wherein the permeation modulator is used in conjunction with a solvent system comprising an aromatic alcohol or a biologically acceptable benzene derivative, with or without an admixture of monoglycerides and a fatty acid ester.
Dependencies are inferred from the claim text.